SCHEMBL9105899

SCHEMBL9105899

COC(=O)c1ccc(C=CC(Cc2ccc(C)c(C)c2)c2cccc(F)c2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.42
RAB9A P51151 4/20 0.42
NPC1 O15118 3/20 0.42
POLB P06746 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
CTDSP1 Q9GZU7 1/20 0.42
MAPT P10636 5/20 0.42
MEN1 O00255 3/20 0.42
LMNA P02545 5/20 0.38
MRGPRX4 Q96LA9 1/20 0.38
HTT P42858 1/20 0.38
NR1H4 Q96RI1 2/20 0.37
PTPN1 P18031 1/20 0.37
GAA P10253 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.36
LOXL2 Q9Y4K0 1/20 0.36
SIRT5 Q9NXA8 1/20 0.36
MAOB P27338 1/20 0.36
DPP4 P27487 2/20 0.35
TP53 P04637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9105886 1.00 KMT2A (0.42) KMT2ARAB9ANPC1POLBSMN1; SMN2
SCHEMBL9109400 0.89 NR1H4 (0.38) POLBMAPTMRGPRX4NR1H4
SCHEMBL27919794 0.89 KMT2A (0.44) KMT2ARAB9ANPC1POLBSMN1; SMN2
SCHEMBL9109392 0.89 NR1H4 (0.38) POLBMAPTMRGPRX4NR1H4
SCHEMBL9106626 0.85 NFE2L2 (0.36) NR1H4MAOBHDAC4HDAC7HDAC5
SCHEMBL9106619 0.85 NFE2L2 (0.36) NR1H4MAOBHDAC4HDAC7HDAC5
SCHEMBL9110879 0.84 NFE2L2 (0.35) NR1H4MAOBHDAC4HDAC7HDAC5
SCHEMBL9110889 0.84 NFE2L2 (0.35) NR1H4MAOBHDAC4HDAC7HDAC5
SCHEMBL9109421 0.82 S1PR1 (0.47) HDAC3HDAC1HDAC2HDAC8OPRM1
SCHEMBL9109429 0.82 S1PR1 (0.47) HDAC3HDAC1HDAC2HDAC8OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8993553-B2 Azetidine derivatives as sphingosine 1-phosphate (S1P) receptor modulators ALLERGAN, INC. (US) 2015-03-31 US disclosed
US-20130310359-A1 NOVEL AZETIDINE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS ALLERGAN, INC. (US) 2013-11-21 US disclosed
EP-2646415-A1 NOVEL AZETIDINE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS Allergan, Inc. (US) 2013-10-09 EP disclosed
EP-2646405-A1 ALKYNE AND ALKENE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE-1 RECEPTOR MODULATORS Allergan, Inc. (US) 2013-10-09 EP disclosed
US-8541397-B2 Alkyne and alkene derivatives as sphingosine 1-phosphate-1 receptor modulators ALLERGAN, INC. (US) 2013-09-24 US disclosed
US-8492561-B2 Azetidine derivatives as sphingosine 1-phosphate (S1P) receptor modulators ALLERGAN, INC. (US) 2013-07-23 US disclosed
US-20130150331-A1 ALKYNE AND ALKENE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE-1 RECEPTOR MODULATORS ALLERGAN, INC. (US) 2013-06-13 US disclosed
US-8404663-B2 Alkyne and alkene derivatives as sphingosine 1-phosphate-1 receptor modulators ALLERGAN, INC. (US) 2013-03-26 US disclosed
US-20120142662-A1 NOVEL AZETIDINE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS ALLERGAN, INC. (US) 2012-06-07 US disclosed
US-20120142640-A1 ALKYNE AND ALKENE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE-1 RECEPTOR MODULATORS ALLERGAN, INC. (US) 2012-06-07 US disclosed
WO-2012074926-A1 NOVEL AZETIDINE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS ALLERGAN, INC. (US) 2012-06-07 WO disclosed
WO-2012074921-A1 ALKYNE AND ALKENE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE-1 RECEPTOR MODULATORS ALLERGAN, INC. (US) 2012-06-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130310359-A1 NOVEL AZETIDINE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS S1PR1, S1PR2, S1PR5 KMT2A 3390/4885RAB9A 446/4885NPC1 262/4885
US-20130150331-A1 ALKYNE AND ALKENE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE-1 RECEPTOR MODULATORS S1PR1, S1PR3, S1PR2 KMT2A 4162/4885RAB9A 2324/4885NPC1 358/4885
US-20120142640-A1 ALKYNE AND ALKENE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE-1 RECEPTOR MODULATORS S1PR1, S1PR3, S1PR2 KMT2A 4162/4885RAB9A 2324/4885NPC1 358/4885
US-20120142662-A1 NOVEL AZETIDINE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS S1PR1, S1PR2, S1PR5 KMT2A 3390/4885RAB9A 446/4885NPC1 262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.